Alessandro Manzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alessandro Manzo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Carla Colombo
Department of Endocrine and Metabolic Diseases, Endocrine Oncology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy
1 shared publication - Delfina Tosi
University of Milan
1 shared publication - Giacomo Gazzano
Pathology Unit, IRCCS Istituto Auxologico Italiano , Milan
1 shared publication - Gianlorenzo Dionigi
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
1 shared publication - Laura Fugazzola
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
1 shared publication - Luca Persani
Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
1 shared publication
Latest Publications
- 1 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (10) , e3353-e3365
TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer
Context: No data are available about the possible association of TP53 mutations and the response to multikinase inhibitors (MKIs) in thyroid cancer (TC). Objective: We evaluated the effect of TP53 mutations on the response to lenvatinib (LEN) in advanced TCs and in vitro models. Methods: We investigated the molecular profile, including TP53 mutations, of 30 tumor tissues from patients treated with LEN, and tested p53 status by immunohistochemistry. These data were compared with clinical-pathological features, and tumor response to LEN. The response to LEN was also evaluated in TP53-defective and TP53-proficient TC cell lines. Results: TP53 mutations significantly correlated with a poor response to LEN (P = .005). TP53-mutated patients had a shorter progression-free survival (PFS) (P < .0001) and overall survival (OS) rates (P = .0007). Accordingly, patients harboring altered nuclear p53 protein expression had shorter PFS and OS (P = .0001 and P = .0056, respectively). These data were confirmed in a validation cohort. In accordance with clinical data, TC cell lines with p53 alterations had low or null sensitivity, while those with TP53 wild-type showed different degrees of sensitivity, primarily due to the increased number of tumor cells in G1 phase, consistent with the cytostatic effect of LEN. Conclusion: We show for the first time in advanced TC that the presence of TP53 alterations is a predictor of poor response to LEN treatment and is associated with worse PFS and OS rates. The evaluation of TP53 mutations/p53 expression might be included in the patient/tumor characterization to be performed before starting an MKI treatment.
- 1 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (10) , e3353-e3365
TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer
Context: No data are available about the possible association of TP53 mutations and the response to multikinase inhibitors (MKIs) in thyroid cancer (TC). Objective: We evaluated the effect of TP53 mutations on the response to lenvatinib (LEN) in advanced TCs and in vitro models. Methods: We investigated the molecular profile, including TP53 mutations, of 30 tumor tissues from patients treated with LEN, and tested p53 status by immunohistochemistry. These data were compared with clinical-pathological features, and tumor response to LEN. The response to LEN was also evaluated in TP53-defective and TP53-proficient TC cell lines. Results: TP53 mutations significantly correlated with a poor response to LEN (P = .005). TP53-mutated patients had a shorter progression-free survival (PFS) (P < .0001) and overall survival (OS) rates (P = .0007). Accordingly, patients harboring altered nuclear p53 protein expression had shorter PFS and OS (P = .0001 and P = .0056, respectively). These data were confirmed in a validation cohort. In accordance with clinical data, TC cell lines with p53 alterations had low or null sensitivity, while those with TP53 wild-type showed different degrees of sensitivity, primarily due to the increased number of tumor cells in G1 phase, consistent with the cytostatic effect of LEN. Conclusion: We show for the first time in advanced TC that the presence of TP53 alterations is a predictor of poor response to LEN treatment and is associated with worse PFS and OS rates. The evaluation of TP53 mutations/p53 expression might be included in the patient/tumor characterization to be performed before starting an MKI treatment.